🇺🇸 FDA

Intelligence Platform

Patents

Browse 67 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10618967

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10562970

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10537611

Methods of treating lung cancer

Five Prime Therapeutics, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273281

CD80 extracellular domain polypeptides and their use in cancer treatment

Five Prime Therapeutics, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221243

Methods of treating conditions with antibodies that bind colony stimulating factor 1 recep

Five Prime Therapeutics, Inc. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10172937

Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

Five Prime Therapeutics, Inc. · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10040858

Anti-CSF1R antibodies for treating PVNS

Five Prime Therapeutics, Inc. · Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10016484

Methods of treating lung cancer

Five Prime Therapeutics, Inc. · Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9957327

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9775881

Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

Five Prime Therapeutics, Inc. · Granted Tue Oct 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9765147

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9695243

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475871

Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

Five Prime Therapeutics, Inc. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9200075

Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9192683

Methods of treating disease with FGFR1 fusion proteins

Five Prime Therapeutics, Inc. · Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9173957

FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

Five Prime Therapeutics, Inc. · Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9175065

FGFR extracellular domain acidic region muteins

Five Prime Therapeutics, Inc. · Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9169313

Method of treatment of cancers characterized by ligand-dependent activating mutations in F

Five Prime Therapeutics, Inc. · Granted Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8951972

FGFR1 extracellular domain combination therapies for lung cancer

Five Prime Therapeutics, Inc. · Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8920800

Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

Five Prime Therapeutics, Inc. · Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8747845

Methods of treatment by administering antibodies that bind colony stimulating factor 1 rec

Five Prime Therapeutics, Inc. · Granted Tue Jun 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8685931

Hair growth methods using FGFR3 extracellular domains

Five Prime Therapeutics, Inc. · Granted Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8614183

Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-depen

Five Prime Therapeutics, Inc. · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted